COSTA MESA, Calif.--(BUSINESS WIRE)--Synthetic Blood International, Inc. (OTCBB:SYBD) announces positive findings from a preliminary analysis of a Phase IIa clinical trial with Oxycyte™ in eight patients with traumatic brain injury. Data from this open-label, proof-of-concept, single-site study demonstrate that Oxycyte increases brain oxygen tension and glucose metabolism compared to baseline, and favorably affects other brain chemistries that impact clinical outcomes in patients with traumatic brain injury. This data was compiled and analyzed by Virginia Commonwealth University.
